Non-Small Cell Lung Cancer
We recommend
Brigatinib in the Therapy of Pretreated Patients with Advanced ALK-Positive NSCLC
A French study analyzed clinical data of pretreated ALK-positive patients with advanced non-small cell lung cancer (NSCLC) and examined the efficacy of next-generation ALK inhibitors – brigatinib, followed by lorlatinib – in real-world clinical practice.
Brigatinib in Patients with ALK+ NSCLC – Final Results of the J-ALTA Clinical Study
At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early…
Impact of Depth of Treatment Response on Outcomes of ALK+ NSCLC Treatment with Brigatinib and Crizotinib
Brigatinib inhibits anaplastic lymphoma kinase (ALK) and its notable advantage is its strong effect…
Articles on this topic
From Biomarker Testing to NSCLC Treatment Selection
During a satellite symposium at this year's European Lung Cancer Congress (ELCC 2022), Prof.…
Efficacy of Brigatinib in Patients with Metastatic NSCLC − Real-World Clinical Data
The journal Lung Cancer published the results of a retrospective analysis of the efficacy of…
Brigatinib in the Therapy of ALK-Positive NSCLC in Patients Refractory to Crizotinib Therapy – Results of the Final Analysis of Clinical Studies
Previously published results of clinical studies have shown that in patients refractory to…
Brigatinib in the Therapy of ALK-Positive NSCLC – First Results of the J-ALTA Study
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity…
Current Results of Brigatinib in the Treatment of Lung Cancer
The results of the primary analysis showed a significant extension of PFS in patients with…
Brigatinib vs. Crizotinib in the Treatment of ALK-Positive NSCLC – Results of the Second Interim Analysis of the ALTA-1L Study
The anaplastic lymphoma kinase inhibitor brigatinib demonstrated superiority over crizotinib…
Good Efficacy of Brigatinib After Failure of 2nd Generation ALK Inhibitors
Brigatinib is commonly used in the treatment of ALK-positive non-small cell lung cancer…
Most read on this topic
Related topic
- From Biomarker Testing to NSCLC Treatment Selection
- Current Results of Brigatinib in the Treatment of Lung Cancer
- Brigatinib in Patients with ALK+ NSCLC – Final Results of the J-ALTA Clinical Study
- Brigatinib vs. Crizotinib in the Treatment of ALK-Positive NSCLC – Results of the Second Interim Analysis of the ALTA-1L Study
- Brigatinib in the Therapy of Pretreated Patients with Advanced ALK-Positive NSCLC
- Good Efficacy of Brigatinib After Failure of 2nd Generation ALK Inhibitors
Related topic